about
CpG-based immunotherapy impairs antitumor activity of BRAF inhibitors in a B-cell-dependent mannerN-dihydrogalactochitosan as a potent immune activator for dendritic cells.Toll-like Receptors in the Vascular System: Sensing the Dangers Within.IL-4 blockade alters the tumor microenvironment and augments the response to cancer immunotherapy in a mouse model.Tumor-Associated Macrophages as Target for Antitumor Therapy.A new marine-derived sulfoglycolipid triggers dendritic cell activation and immune adjuvant response.Targeting of C-type lectin-like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides.Impact of dose, route, and composition on the immunogenicity of immune polyelectrolyte multilayers delivered on gold templates.Inflammatory monocytes regulate Th1 oriented immunity to CpG adjuvanted protein vaccines through production of IL-12.Codon-Optimized P1A-Encoding DNA Vaccine: Toward a Therapeutic Vaccination against P815 MastocytomaThe novel functional nucleic acid iRed effectively regulates target genes following cytoplasmic delivery by faint electric treatment.Activation and selective IL-17 response of human Vγ9Vδ2 T lymphocytes by TLR-activated plasmacytoid dendritic cellsDisplay of DNA on Nanoparticles for Targeting Antigen Presenting Cells.The influence of adjuvant on UreB protection against Helicobacter pylori through the diversity of CD4+ T-cell epitope repertoire.Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.PeptoSomes for Vaccination: Combining Antigen and Adjuvant in Polypept(o)ide-Based Polymersomes.Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy.Modified FeO Magnetic Nanoparticle Delivery of CpG Inhibits Tumor Growth and Spontaneous Pulmonary Metastases to Enhance Immunotherapy
P2860
Q33902560-6DAAC62F-CBBE-4F20-87C0-590EFDAE86EBQ36234323-D958CC6F-8800-4CC1-B245-52BFA5A3BF0CQ36453194-39349D8B-990B-4440-B6D6-4396A4A17123Q38667135-FCF31E0B-1EA9-4DE2-AA6D-2648CD1969BFQ39403895-A928693C-1087-4DBE-A7E7-5320AE369BF3Q40121621-41142D0A-B5E7-471C-88F4-D3227E27A34EQ40293384-C8407728-285D-4DC7-A63D-468AEFA3453AQ40561184-5A7C10FC-4BCB-4FC1-813E-F1A376A3AC6FQ41074599-9565F039-30ED-4F91-8B4C-AF6EA9141679Q41191220-3FA05F24-FC29-4796-9F1C-5FE4A1F87252Q41872943-F2245A2A-F8A0-4C14-8F7C-9ADB00386407Q41944197-CE3BEA56-8C95-44B4-8DB6-8E9951D15F7DQ42099934-FD6A7BCE-CC71-4C88-8153-F30C3035C868Q42366604-AB7467C6-5947-470A-A80A-B440215F4776Q48246344-6063206D-C7D6-4F2C-BC8A-216A36B98CA2Q48320248-9FEFD728-CA74-49A3-98DC-E952B4599063Q48508291-0809CC3C-75A5-4486-AB76-2EB2A88A4B9DQ58771490-34046E28-9B9F-4E74-8C2C-CDFF14BE1ACC
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
CpG Oligonucleotides as Cancer Vaccine Adjuvants
@ast
CpG Oligonucleotides as Cancer Vaccine Adjuvants
@en
CpG Oligonucleotides as Cancer Vaccine Adjuvants
@nl
type
label
CpG Oligonucleotides as Cancer Vaccine Adjuvants
@ast
CpG Oligonucleotides as Cancer Vaccine Adjuvants
@en
CpG Oligonucleotides as Cancer Vaccine Adjuvants
@nl
prefLabel
CpG Oligonucleotides as Cancer Vaccine Adjuvants
@ast
CpG Oligonucleotides as Cancer Vaccine Adjuvants
@en
CpG Oligonucleotides as Cancer Vaccine Adjuvants
@nl
P2093
P2860
P3181
P356
P1433
P1476
CpG Oligonucleotides as Cancer Vaccine Adjuvants
@en
P2093
Debra Tross
Dennis M Klinman
Hidekazu Shirota
P2860
P304
P3181
P356
10.3390/VACCINES3020390
P407
P577
2015-01-01T00:00:00Z